2009
Three Hundred and One Consecutive Extended Right Hepatectomies
Kishi Y, Abdalla EK, Chun YS, Zorzi D, Madoff DC, Wallace MJ, Curley SA, Vauthey JN. Three Hundred and One Consecutive Extended Right Hepatectomies. Annals Of Surgery 2009, 127: 171-179. PMID: 19730239, DOI: 10.1097/sla.0b013e3181b674df.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBilirubinChildChi-Square DistributionEmbolization, TherapeuticEndpoint DeterminationFemaleHepatectomyHumansLiverLiver Function TestsLogistic ModelsMaleMiddle AgedOutcome and Process Assessment, Health CarePatient SelectionPortal VeinPostoperative ComplicationsPreoperative CareRetrospective StudiesRisk FactorsStatistics, NonparametricConceptsPreoperative portal vein embolizationPostoperative liver insufficiencySafe hepatic resectionPreoperative PVEExtended right hepatectomyLiver insufficiencyRight hepatectomyHepatic resectionPostoperative outcomesEnd pointLiver volumetryIntraoperative blood transfusionPrimary end pointSecondary end pointsLiver volume ratioPortal vein embolizationShort-term outcomesBody mass indexTotal liver volumeMultivariate logistic regressionFLR volumeFuture liverVein embolizationBlood transfusionConsecutive patients
2008
Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases
Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN. Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases. Annals Of Surgical Oncology 2008, 15: 2765. PMID: 18636296, PMCID: PMC5901734, DOI: 10.1245/s10434-008-0035-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsEmbolization, TherapeuticFemaleFollow-Up StudiesHumansLiver NeoplasmsLiver RegenerationMaleMiddle AgedOrganoplatinum CompoundsOxaliplatinPortal VeinPrognosisProspective StudiesSurvival RateTreatment OutcomeConceptsPortal vein embolizationColorectal liver metastasesVascular endothelial growth factorLiver metastasesLiver regenerationPreoperative chemotherapyFLR hypertrophyLiver resectionVein embolizationFuture liver remnant volumeFLR volume increaseMajor liver resectionLiver remnant volumeEffect of chemotherapyImpairs liver regenerationEndothelial growth factorConclusionPreoperative chemotherapyConcurrent bevacizumabProspective databaseRight hepatectomyPostoperative outcomesConsecutive patientsRemnant volumeBevacizumabMurine model
2005
Percutaneous Radiofrequency Ablation of Renal Tumors: Technique, Complications, and Outcomes
Ahrar K, Matin S, Wood CG, Wallace MJ, Gupta S, Madoff DC, Rao S, Tannir NM, Jonasch E, Pisters LL, Rozner MA, Kennamer DL, Hicks ME. Percutaneous Radiofrequency Ablation of Renal Tumors: Technique, Complications, and Outcomes. Journal Of Vascular And Interventional Radiology 2005, 16: 679-688. PMID: 15872323, DOI: 10.1097/01.rvi.0000153589.10908.5f.Peer-Reviewed Original ResearchConceptsPercutaneous radiofrequency ablationPercutaneous RF ablationRenal tumorsGross hematuriaPrimary tumorTechnical successRF ablationRadiofrequency ablationHigh technical success rateAbdominal wall weaknessTechnical success rateSignificant clinical sequelaeAnterior abdominal wallComputed tomography guidanceClinical sequelaeMinor complicationsRenal functionTransient paresthesiaConsecutive patientsMajor complicationsUrinary obstructionOvernight observationGeneral anesthesiaTomography guidanceMedical records